TY -非盟的吉利·Margalida AU -卡斯特罗,Adoracion盟——Garcia-Palacios Azucena盟——Garcia-Campayo哈维尔盟——Mayoral-Cleries佛明非盟- Botella,克里斯蒂娜AU -罗卡,Miquel盟——Barcelo-Soler Alberto AU - Hurtado玛丽亚M AU -纳瓦罗,MªTeresa AU - Villena阿米莉亚盟——Perez-Ara M洛杉矶AU - Riera-Serra,加索尔盟——Banos罗莎MªPY - 2020 DA - 2020/6/5 TI -有效性三个低强度、网络心理干预治疗抑郁症在初级保健:背景:初级保健是抑郁症初始治疗的主要途径，但对这些患者的管理远非最佳。初级保健缺乏时间是提供循证心理治疗的主要困难之一。在过去的十年中，研究主要集中在基于认知行为疗法(CBT)的短期心理治疗和经济有效的基于互联网的干预措施的发展上。很少有研究关注使用CBT治疗抑郁症的替代方法。因此，有必要研究其他治疗方法。目的:本研究旨在评估3种低强度、基于网络的心理干预(健康生活方式心理教育计划[HLP]、积极情感促进重点计划[PAPP]和基于正念的短暂干预[MP])与对照组(照常改善治疗[iTAU])的效果。方法:于2015年3月至2016年3月进行多中心、四组、平行随机对照试验，随访12个月。总共从西班牙3个地区的初级保健机构招募了221名患有轻度或中度重度抑郁症的成年人。患者随机分为iTAU组(n=57)、HLP组(n=54)、PAPP组(n=56)和MP组(n=54)。 All patients received iTAU from their general practitioners. The main outcome was the Spanish version of the Patient Health Questionnaire-9 (PHQ-9) from pretreatment (time 1) to posttreatment (time 2) and up to 6 (time 3) and 12 (time 4) months’ follow-up. Secondary outcomes included the visual analog scale of the EuroQol, the Short-Form Health Survey (SF-12), the Positive and Negative Affect Schedule (PANAS), and the Pemberton Happiness Index (PHI). We conducted regression models to estimate outcome differences along study stages. Results: A moderate decrease was detected in PHQ-9 scores from HLP (β=–3.05; P=.01) and MP (β=–3.00; P=.01) compared with iTAU at posttreatment. There were significant differences between all intervention groups and iTAU in physical SF-12 scores at 6 months after treatment. Regarding well-being, MP and PAPP reported better PHI results than iTAU at 6 months post treatment. PAPP intervention significantly decreased PANAS negative affect scores compared with iTAU 12 months after treatment. Conclusions: The low-intensity, internet-based psychological interventions (HLP and MP) for the treatment of depression in primary care are more effective than iTAU at posttreatment. Moreover, all low-intensity psychological interventions are also effective in improving medium- and long-term quality of life. PAPP is effective for improving health-related quality of life, negative affect, and well-being in patients with depression. Nevertheless, it is important to examine possible reasons that could be implicated for PAPP not being effective in reducing depressive symptomatology; in addition, more research is still needed to assess the cost-effectiveness analysis of these interventions. Trial Registration: ISRCTN Registry ISRCTN82388279; http://www.isrctn.com/ISRCTN82388279 International Registered Report Identifier (IRRID): RR2-10.1186/s12888-015-0475-0 SN - 1438-8871 UR - //www.mybigtv.com/2020/6/e15845 UR - https://doi.org/10.2196/15845 UR - http://www.ncbi.nlm.nih.gov/pubmed/32501276 DO - 10.2196/15845 ID - info:doi/10.2196/15845 ER -